Clinical Trial Update: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update outlines a study evaluating the pharmacokinetics, efficacy, safety, tolerability, and pharmacodynamics of satralizumab in ped…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Status: RECRUITING